Enabling paediatric clinical research
- Global Accelerator for Paediatric Formulations Network (GAP-f)
- Enabling paediatric clinical research
- Members
- Access and delivery
- Governance
- Prioritized portfolio
- Product development
- Resources
GAP-f supports the generation of evidence for children's medicines. Three tools bring together what researchers, funders and regulators need: where trials can be run, how to include children, and how to design studies that work.
- Paediatric Clinical Trial Site Map
- Knowledge Portal for Including Children in Clinical Trials
- Optimizing Study Design for Novel Paediatric Medicines
Paediatric Clinical Trial Site Map
The paediatric clinical trial site map summarizes information collected from a survey disseminated through partners and WHO networks. It aims to increase the visibility of sites with experience in clinical trials with children and facilitate collaboration among research sites, sponsors, and funders. For inquiries, contact gap-f@who.int.
About the site map and survey
Expand this section to learn more about how the site map was created and view selected results from the survey.
The paediatric clinical trial site map summarizes information collected from a survey designed by GAP-f, with the goal of mapping clinical research sites with capacity to conduct paediatric clinical trials that inform approval and optimal use of paediatric medicines and formulations. The survey was modelled after existing site surveys and self-assessment tools developed by GAP-f partners and reviewed by a group of paediatric clinical researchers. The survey was programmed in the DataForm electronic data capture platform, pre-tested by selected sites, revised and finalized before distribution. The survey was disseminated through convenience sampling to GAP-f partners and WHO networks.
A total of 424 clinical research sites, across 80 countries, responded to this survey. Of these sites, 304 (72%) reported having conducted clinical trials involving children in the past 5 years. These 304 sites are included in the map.
The map is an ongoing initiative, and new sites will be added as additional survey results become available. The survey also sought to identify areas where additional support may be needed to prepare sites for future paediatric studies and to inform GAP-f initiatives to strengthen the clinical trial ecosystem. While site-level data remains confidential and for internal use only, selected aggregate results will be published in due course.



Knowledge Portal for Including Children in Clinical Trials
Optimizing Study Design for Novel Paediatric Medicines
GAP-f facilitates engagement between regulators, industry, and public health stakeholders to optimize clinical study design and evidence generation for novel paediatric medicines, particularly where clinical development plans are misaligned with public health needs. Reports from consultations on antibiotics, HIV broadly neutralizing antibodies, and respiratory syncytial virus (RSV) are available below.
Accelerating optimal approval of priority formulations for antibiotic use in children: meetings report,...
On 24 March 2023, WHO launched the first-ever list of priority paediatric formulations for antibiotics, addressing critical gaps in age-appropriate treatments...
WHO consultation on the use of broadly neutralizing antibodies for postnatal prophylaxis against the...
Building on growing momentum from multiple stakeholders, this report summarizes the proceedings from a consultation held to convene a multidisciplinary...
Prevention and treatment of respiratory syncytial virus disease among children: study design optimization...
Respiratory syncytial virus (RSV) is a major cause of severe respiratory illness and mortality among young children, particularly in low- and middle-income...